LATANOPROST;17-PHENYL-13,14-DIHYDRO TRINOR PROSTAGLANDIN F2ALPHA
Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a
topical medication used for controlling the progression of glaucoma
or ocular hypertension by reducing intraocular pressure. It is a
prostaglandin analogue (more specifically an analogue of
prostaglandin F2) that works by increasing the outflow of
aqueous fluid from the eyes (through the uvealsclearal tract).
It is also known by the brand name of Xalatan manufactured by
Pfizer. Annual sales are approximately $1.6 billion. The patent for
latanoprost expired in March 2011, and at least one generic version
(manufactured by Mylan Inc.) is now widely available in the U.S.
The Veterans Health Administration, part of the U.S. Department of
Veterans Affairs, uses generic Latanoprost manufactured by Alcon
Laboratories of Fort Worth, Texas distributed by Novartis generic
brand Sandoz Pharmaceuticals.
Latanoprost was developed by Carl B. Camras and his research
adviser Lszl Z. Bit at Columbia University in 1996.